VRDN
Viridian Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow -3.8% ·
net new positions +15.4%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | -12 | 71.65M | $1.32B | +6 | −18 |
| Q1 2026 | 88 | +7 | 66.96M | $1.32B | +11 | −5 |
| Q4 2025 | 82 | +2 | 62.58M | $1.95B | +4 | −1 |
| Q3 2025 | 16 | -1 | 34.97M | $754.70M | — | −1 |
| Q2 2025 | 14 | -2 | 33.44M | $467.46M | — | −2 |
| Q1 2025 | 13 | +2 | 10.47M | $141.20M | +2 | — |
| Q4 2024 | 11 | -2 | 10.88M | $208.63M | — | −2 |
| Q3 2024 | 12 | +3 | 5.78M | $131.57M | +3 | — |
| Q2 2024 | 9 | — | 3.15M | $40.97M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.87M | -18.6% | $38.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.72M | +3.7% | $23.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.72M | +3.7% | $23.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.69M | +27.2% | $22.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.69M | +27.2% | $22.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 1.11M | -33.3% | $15.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 1.08M | New | $14.61M | 0.0% | New | 1 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 537.02K | +3.7% | $7.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 320.30K | -13.7% | $4.32M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 297.97K | -18.6% | $4.02M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Wellington Management ✦ | 249.17K | +11.0% | $3.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 222.40K | -47.6% | $3.00M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 204.70K | New | $2.76M | 0.0% | New | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 88.55K | -75.3% | $1.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 88.55K | -75.3% | $1.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 81.38K | -81.6% | $1.10M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $14.61M | 0.0% |
| Point72 Asset Management | $2.76M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 111.32M shares, $2.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.21K sh · $103,194
Officer · 10.00K sh · $245,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology